Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Clinical trial NCT03805841 · TERMINATED

Trial details

NCT number: NCT03805841
Sponsor: Rain Oncology Inc
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC, Stage IV NSCLC Stage IIIB NSCLC, Stage IIIC NSCLC, Recurrent EGFR Exon 20 Insertion Mutation HER2-activating Mutation ERBB Fusion NRG1 Fusion

Start date: 2019-03-13
Primary completion: 2021-04-09
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.